Premature Ovarian Failure (Genetic and Physiopathologic Analysis) (GéNIOP)

Study Description

Go to 

Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Brief Summary:

Premature Ovarian Failure (POF), syndrome observed in young woman, present consequences on hormonal and leads at definitive infertility. It's a rare and complex syndrome and for this reason, we propose to initiate a collaborative team network to understand better his genetic and physiopathology.

We are going to realize a global study of this syndrome with clinical and fundamentals approaches. We wish that this project allows us to understand better the physiopathology of this rare disease. Finally, POF responsible genes identification is the base for future development of therapeutics approaches.

Condition or disease
Premature Ovarian Failure

Detailed Description:

Premature ovarian failure (POF) is a rare but not exceptional disease concerning 0.1% of the more-than-thirty-years-old women. On the clinical aspect, patients present a primary or secondary amenorrhea depending on when the disease occurs in their lives. Infertility is most of the time definitive and the yet only available therapy is auto implantation of cryopreserved oocytes. Initiation of a substitutive hormonal treatment is also necessary to prevent the consequences of estrogenic hardship (i.e leading to osteoporosis).

POF has numerous possible origins, and can be linked to auto-immune diseases, metabolic disorders (i.e. galactosemia) or even genetic abnormalities. According to her origin, POF is characterized by (a) a depletion of primary follicles, (b) increased or accelerated follicle atresia (c) an alteration of the recruitment of dominant follicle and (d) stopped follicular maturation.

The purpose of our work is to organize a clinical and fundamental research network focussed on premature ovarian failure (POF). It will aim to collect clinical, biological, radiological and histological information on patients, and according to their phenotypes, to decide for searching possible genetic abnormalities leading to POF. And in the same time, the constitution of a broad tissue collection allows the study of ovarian transcripts, using POF as a pathologic model to describe ovaries and follicle development-involved genes.

Study Design

Go to 

Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type :	Observational
Estimated Enrollment :	87 participants
Time Perspective:	Cross-Sectional
Official Title:	Premature Ovarian Failure : Genetic and Physiopathologic Analysis
Study Start Date :	March 2005
Estimated Primary Completion Date :	March 2009
Estimated Study Completion Date :	March 2009

Groups and Cohorts

Go to 

Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort
1; POF patients; 18 years <Age> 40 years; Hormonal sampling; FMR1 analysis; FSH Receptor gene analysis; LH Receptor gene analysis; BMP15 gene analysis; GDF9 gene analysis; Connexin 37 analysis; Ovarian biopsy; Bone Mineral Density; Pelvic Ultrasonography;
2; Control Group No POF patients; Benign ovarian pathology; 18 years <Age> 40 years; Hormonal sampling; FMR1 analyze; FSH Receptor gene analysis; LH Receptor gene analysis; BMP15 gene analysis; GDF9 gene analysis; Connexin 37 analysis; Ovarian biopsy under specific conditions; Bone Mineral Density; Pelvic Ultrasonography

Outcome Measures

Go to 

Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Biospecimen Retention:   Samples With DNA

One ovarian biopsy during the protocol to evaluate ovocytes number and transcriptome analysis.

Eligibility Criteria

Go to 

Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Ages Eligible for Study:	18 Years to 39 Years (Adult)
Sexes Eligible for Study:	Female
Accepts Healthy Volunteers:	Yes
Sampling Method:	Non-Probability Sample

Study Population

POF patients & controls

Criteria

Inclusion criteria :

Experimental group:

• 18 years <Age> 39 years
• Patient with amenorrhea since at least 3 months
• Patient with at least 1 FSH dosage > 30 mUI/L
• Patients between 40 and 45 years old with hormonal results indicating a POF declared before 39 years old will be included.
• Informed Consent Form Signature

Control group:

• 18 years <Age> 39 years
• Patient having a benign ovarian pathology justifying an ovarian surgery
• Informed Consent Form Signature

Exclusion criteria:

Contacts and Locations

Go to 

Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Contacts

Contact: Philippe Touraine, MD, PhD	+33 1 42 16 02 11	philippe.touraine@psl.aphp.fr

Locations

France
Groupe Hopitalier Pitié-Salpêtrière	Recruiting
Paris, France, 75013
Contact: Philippe Touraine, MD, PhD +33 1 42 16 02 11

Sponsors and Collaborators

Assistance Publique - Hôpitaux de Paris

Investigators

Principal Investigator:	Philippe Touraine, MD, PhD	Assistance Publique - Hôpitaux de Paris

More Information

Go to 

Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Responsible Party:	Myriem Carrier, Department Clinical Research of Developpement
ClinicalTrials.gov Identifier:	NCT00780897 History of Changes
Other Study ID Numbers:	P040801
First Posted:	October 28, 2008
Last Update Posted:	October 28, 2008
Last Verified:	October 2008

Keywords provided by Assistance Publique - Hôpitaux de Paris:

PREMATURE OVARIAN FAILURE (POF); GENETIC ANALYSIS; PHYSIOPATHOLOGIC ANALYSIS

Additional relevant MeSH terms:

Premature Birth; Primary Ovarian Insufficiency; Menopause, Premature; Obstetric Labor, Premature; Obstetric Labor Complications; Pregnancy Complications	Ovarian Diseases; Adnexal Diseases; Genital Diseases, Female; Gonadal Disorders; Endocrine System Diseases